Hypothesis

In aged tissues, senescent fibroblasts release extracellular vesicles enriched in miR-23a-3p that are taken up by resident macrophages, where the miRNA directly suppresses HAS2 transcription. This reduces macrophage‑derived high‑molecular‑weight HA (HMW‑HA) and shifts their hyaluronan output toward low‑molecular‑weight fragments (LMW‑HA). The macrophage‑derived LMW‑HA then acts in an autocrine/paracrine fashion to engage TLR2/TLR4/CD44 on the same macrophages, sustaining NF‑κB activation and SASP secretion. Consequently, a macrophage‑intrinsic glycan damage loop amplifies fibroblast senescence, creating a self‑reinforcing circuit that drives tissue aging independently of extrinsic cues.

Mechanistic Rationale

The fibroblast‑to‑macrophage miR-23a-3p transfer provides a direct link between the established fibroblast senescence‑HA axis and immune cell function. Macrophages, like fibroblasts, rely on HAS2 to generate the protective HMW‑HA coat that dampens TLR signaling. Loss of this coat converts macrophages from a surveillant to an inflammatory state, mirroring the fibroblast phenotype. The resulting LMW‑HA serves as a DAMP that not only activates TLRs but also feeds back to inhibit HAS2 via ERK1/2 signaling, as shown for fibroblast collagen fragments. Thus, the loop is not limited to the stromal compartment; it is propagated by the immune cells that are supposed to clear senescent cells.

Testable Predictions

1. Inhibition of miR-23a-3p in macrophages (using antagomiRs or CRISPR‑Cas13) will restore HAS2 expression, increase HMW‑HA secretion, and reduce TLR‑dependent NF‑κB activation in aged mouse skin.
2. Macrophage‑specific overexpression of HAS2 will resist the pro‑inflammatory shift induced by fibroblast‑derived vesicles and attenuate SASP production in co‑culture.
3. In vivo, lysosomal delivery of HMW‑HA to macrophages will break the autocrine LMW‑HA/TLR loop, leading to decreased MMP release and improved dermal elasticity.
4. Blocking TLR2/TLR4 signaling in macrophages will diminish the feedback suppression of HAS2, uncoupling the loop even when miR-23a-3p remains high.

Potential Experiments

• Isolate extracellular vesicles from senescent human fibroblasts, label with PKH67, and co‑culture with bone‑marrow‑derived macrophages; measure miR-23a-3p uptake by qPCR and HAS2 mRNA/protein by Western blot.
• Treat macrophages with fibroblast‑derived vesicles ± miR-23a-3p antagomiR; quantify HA size distribution by HPLC‑SEC‑MALS and assess TLR signaling via phospho‑p65 ELISA.
• Generate LysM‑Cre;Has2^fl/fl mice to delete HAS2 specifically in macrophages; compare skin histology, HA content, and frailty indices with wild‑type littermates.
• Apply topical HMW‑HA (500–2000 kDa) to aged mouse skin and monitor changes in macrophage phenotype (flow cytometry for CD86/CD206) and collagen degradation (hydroxyproline assay).

If these predictions hold, the data would support the notion that aging is not merely a consequence of immune failure but is actively driven by a macrophage‑intrinsic glycan damage loop that mirrors and amplifies the fibroblast senescence circuit. Targeting this loop—either by restoring macrophage HMW‑HA synthesis or by interrupting LMW‑HA/TLR signaling—should attenuate multiple hallmarks of aging before systemic interventions are required.